Your browser doesn't support javascript.
loading
Evaluating opioid analgesic prescribing limits: A narrative review.
Seitz, Amy E; Janiszewski, Karen A; Guy, Gery P; Tapscott, Ryan T; Einstein, Emily B; Meyer, Tamra E; Tierney, Jessica; Staffa, Judy; Jones, Christopher M; Compton, Wilson M.
Afiliação
  • Seitz AE; Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
  • Janiszewski KA; Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
  • Guy GP; National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Tapscott RT; National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Einstein EB; National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland, USA.
  • Meyer TE; Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
  • Tierney J; Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
  • Staffa J; Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA.
  • Jones CM; National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Compton WM; National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland, USA.
Pharmacoepidemiol Drug Saf ; 31(6): 605-613, 2022 06.
Article em En | MEDLINE | ID: mdl-35247021
PURPOSE: In response to the opioid crisis, opioid analgesic guidelines and prescribing limits have proliferated. The purpose of this narrative review is to examine evidence from studies evaluating the patient or public health impact of federal and state opioid analgesic prescribing guidelines and laws, describe gaps and challenges in current research, and highlight opportunities for improving future research. METHODS: We focused on evidence from a literature review covering 2013 through 2019. We identified 30 studies evaluating opioid analgesic thresholds based on federal policies and guidelines, state laws, and Medicaid state plans that attempt to influence the course of patient care at or when the limit is exceeded (e.g., prior authorization). RESULTS: Most studies evaluated changes in prescribing or dispensing patterns of opioid analgesics, largely finding decreases in prescribing after policy enactment. Fewer studies evaluated patient or public health outcomes beyond changes in prescribing and dispensing patterns; results were infrequently stratified by potentially important sociodemographic and clinical factors. No studies assessed the potential for adverse patient outcomes for which we have emerging evidence of harms. CONCLUSIONS: We describe knowledge gaps and propose opportunities for future research to sufficiently assess the potential impact and unintended consequences of opioid analgesic prescribing laws, regulations, guidelines, and policies.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Padrões de Prática Médica / Analgésicos Opioides Tipo de estudo: Guideline / Prognostic_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: Pharmacoepidemiol Drug Saf Assunto da revista: EPIDEMIOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Padrões de Prática Médica / Analgésicos Opioides Tipo de estudo: Guideline / Prognostic_studies Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: Pharmacoepidemiol Drug Saf Assunto da revista: EPIDEMIOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos